WallStSmart
ZBIO

Zenas BioPharma, Inc. Common Stock

NASDAQ: ZBIO · HEALTHCARE · BIOTECHNOLOGY

$17.55
-2.55% today

Updated 2026-04-29

Market cap
$1.09B
P/E ratio
P/S ratio
109.46x
EPS (TTM)
$-8.44
Dividend yield
52W range
$9 – $45
Volume
0.7M

WallStSmart proprietary scores

23
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D
7.0
Quality
B+
2.5
Profitability
F
5.0
Valuation
C+
4/9
Piotroski F-Score
Moderate
0.9
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target
$42.00
+139.32%
12-Month target
Intrinsic (DCF)
Margin of safety
0 Strong Buy7 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths
+ Debt/equity 0.00x — low leverage
Risks
- Altman Z 0.90 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-82.41M
- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$50.00M$5.00M$10.00M$10.00M
Net income$-119.28M$-37.12M$-156.99M$-377.74M$-240.44M
EPS$-8.44
Free cash flow$-67.85M$-30.55M$-119.81M$-172.35M$-82.41M
Profit margin-74.25%-3,139.76%-3,777.37%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
ZBIO$1.09B233.72.55.07.0Avoid
LLY$760.43B7810.010.05.06.5Strong Buy
JNJ$547.28B594.79.03.36.0-43.54%Buy
ABBV$360.63B634.08.04.75.0-29.31%Buy
UNH$322.34B545.35.57.34.8+42.06%Buy
AZN$294.17B646.78.05.35.0+4.07%Buy

Smart narrative

Zenas BioPharma, Inc. Common Stock trades at $17.55. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 0.90, it sits in the distress. TTM revenue stands at $10.00M.

Frequently asked questions

What is Zenas BioPharma, Inc. Common Stock's stock price?
Zenas BioPharma, Inc. Common Stock (ZBIO) trades at $17.55.
Is Zenas BioPharma, Inc. Common Stock overvalued?
Smart Value Score 23/100 (Grade F, Strong Sell).
What is the price target of Zenas BioPharma, Inc. Common Stock (ZBIO)?
The analyst target price is $42.00, representing +139.3% upside from the current price of $17.55.
What is Zenas BioPharma, Inc. Common Stock's revenue?
TTM revenue is $10.00M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
0.90 — distress.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio109.46x
ROE-136.20%
Beta
50D MA$22.59
200D MA$24.14
Shares out0.06B
Float0.04B
Short ratio
Avg volume0.7M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years